Comparing 2 different kinds of treatment in people with newly diagnosed multiple myeloma

What we are studying

This study has two parts, the first part is related to the initial treatment of your myeloma (also called induction) and a second part is related to continued long term control of the myeloma (also called maintenance). The purpose of the first part of the study is to compare the effects, good and/or bad, of a combination of carfilzomib, lenalidomide and dexamethasone with another combination of bortezomib, lenalidomide and dexamethasone, on study participants and their cancer to find out which is better. In this study, study participants will get either the combination that contains carfilzomib or that containing bortezomib. Study participants will not get both. Following the initial treatment for myeloma (induction), the second part of the study will examine if it is better to continue lenalidomide until the myeloma comes back or limit it for a defined period of 2 years. In this study, lenalidomide will be either stopped after 2 years or study participants will stay on it until the myeloma relapses.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • Hispanic or Latino
  • Ages 18 - 80

Eligibility Criteria

  • Study participants may have received no more than 1 cycle of prior chemotherapy and no more than 160mg of prior dexamethasone

What is involved

  • This study has 2 parts
  • The first part is related to initial treatment of myeloma and the second part is related to continued long term control of the myeloma.

Compensation

None

Contact Information

Study Coordinator
Jennifer Thomas
Email
jethomas@wakehealth.edu
Phone
336-713-6914

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.